Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
April 12, 2023 16:05 ET
|
Ardelyx, Inc.
Three posters support the important role that XPHOZAH, a novel phosphate absorption inhibitor, could potentially play in the treatment of hyperphosphatemia XPHOZAH consistently lowered serum...
Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 02, 2023 16:02 ET
|
Ardelyx, Inc.
Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales Resubmission of XPHOZAH New Drug Application expected in early Q2 2023 Company ends Q4 with...
Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
February 28, 2023 08:00 ET
|
Ardelyx, Inc.
WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
February 27, 2023 08:15 ET
|
Ardelyx, Inc.
WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
February 23, 2023 08:00 ET
|
Ardelyx, Inc.
WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...